IXICO plc Contract expansion with biopharmaceutical company (1763Z)

TIDMIXI

RNS Number : 1763Z

IXICO plc

30 August 2018

30(th) August 2018

IXICO plc

("IXICO" or the "Company")

Expansion of contract with biopharmaceutical company

Total contract value has increased to EUR1.3m

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a further change order to a current contract which increases the total contract value to EUR1.3m.

The original contract in Alzheimer's disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites. The latest amendment results in a total change in the contract value of EUR0.5m or 65% above the original value of EUR0.8m.

Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial.

Giulio Cerroni, Chief Executive Officer of IXICO, said: "We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes."

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive Officer         Tel: +44 20 3763 7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)               Tel: +44 20 7408 4090 
  Edward Mansfield/Anita Ghanekar/Daniel Bush 
 
 FTI Consulting Limited (Investor Relations)    Tel: +44 20 3727 1000 
  Simon Conway/Mo Noonan

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.

IXICO's specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CNTEALPNAAAPEFF

(END) Dow Jones Newswires

August 30, 2018 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024